OpenAI-Backed Red Queen Bio Racing to Design Antibodies for AI-Generated Pathogens

Red Queen Bio, an artificial-intelligence biosecurity startup backed by OpenAI, is designing antibody drugs preemptively to defend against novel pathogens that advanced AI systems could theoretically create, a striking example of how frontier machine learning is now reshaping biological defense strategy. The company, founded in 2025 by Nikolai Eroshenko and Hannu Rajaniemi after spinning out of HelixNano, has raised $36 million to develop medical countermeasures against both naturally occurring and AI-enabled biological threats. The approach reflects a growing conviction among security researchers that computational biology—applying machine learning to antibody design—can accelerate defensive measures faster than the pace of emerging threats.